Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksValiRx Share News (VAL)

Share Price Information for ValiRx (VAL)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 3.25
Bid: 3.20
Ask: 3.30
Change: 0.00 (0.00%)
Spread: 0.10 (3.125%)
Open: 3.25
High: 3.25
Low: 3.25
Prev. Close: 3.25
VAL Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Small caps: Cineworld, Aortech, African Eagle

Mon, 24th May 2010 07:52

Cinema chain Cineworld has signed a deal with Quintain Estates for a new multi-screen cinema at Wembley City, the retail park next door to Wembley station. Cineworld has signed a 25 year lease for a new nine screen cinema which will seat 1,800 people in total and is scheduled to open in 2013. It will be located adjacent to Wembley Stadium and Wembley Arena, forming a central part of the 280,000 sq ft leisure and retail hub. Construction is expected to commence on the site in 2011.Biomaterials and medical devices group Aortech today announced a non-exclusive technology licence and material supply agreement with a multi-billion dollar NYSE listed company to use the group's proprietary biostable co-polymer Elast-Eo as an integral part of a drug delivery platform for urological catheters.African Eagle is "delighted" with results of its phase 2 column and tank leach tests at the Dutwa nickel project in Tanzania.The tests show that Dutwa ore could be processed by either heap leaching or tank leaching at normal atmospheric pressure, without recourse to the high cost and hi-tech complications of high pressure acid leach (HPAL).Green technology company Ultima Networks made a pre-tax profit of £214,000 in 2009, down from £281,000 the previous year, on revenue down to £1.87m from £1.98m. "There remain challenges ahead in the economic conditions we face which will have an impact on all divisions of the business but we are confident that the milestones reached in 2009 will allow us to grow across all areas of the group," the firm said.It's also confident it will be able to raise enough money to build the solar parks planned for southern Italy.ValiRx, the biotech firm focused on cancer diagnostics and therapeutics for personalised medicine, has added an over the counter Chlamydia self-testing kit to its range of health screening products.The company has signed an agreement to market Biovei's Chlamydia kit in the UK and Ireland under ValiRx's SELFCheck brand. The SELFCheck Chlamydia kit will provide a test result within about 10 minutes, compared to a lag of four to five days for a laboratory test. Trading systems developer Patsystems said results for the year to end of April were in line with management's expectations while the company's strong pipeline underpins its belief that 2010 will be another strong year for the group."I am pleased to report that 2010 has started as strongly as we expected with the addition of Bursa Malaysia to our client list, good progress on several other sales prospects and continued double digit growth in our existing Asian client base," said Richard Last, the company's chairman.Oil and gas firm Roxi Petroleum narrowed pre-tax losses to $33.4m against the loss of $94.5m predominantly due to lower admin costs. "These are exciting times for Roxi and its shareholders, as we remain focused on increasing shareholder value in the near term. We are looking forward to a very active and productive period ahead of us," he said.Stratex International rose after the exploration and development company announced "positive results" from detailed sampling of the company's Megenta hot spring gold discovery in Ethiopia.Shares in Max Petroleum fell back after the Kazakhstan-focused oil and gas developer said reservoirs encountered during drilling at the Borkyldakty Field were 'structurally lower than expected, at or below their respective oil-water contacts.'
More News
10 Feb 2020 16:00

UK Shareholder Meetings Calendar - Next 7 Days

UK Shareholder Meetings Calendar - Next 7 Days

Read more
14 Jan 2020 14:50

ValiRx signs letter of intent in a bid to fund VAL401

(Sharecast News) - Clinical-stage biotechnology company ValiRx updated the market on its subsidiary joint venture, ValiSeek, and its cancer therapeutic, VAL401 on Tuesday.

Read more
14 Jan 2020 11:08

ValiRx Joint Venture Partner Enters Agreement For VAL401 Funding

ValiRx Joint Venture Partner Enters Agreement For VAL401 Funding

Read more
6 Jan 2020 09:59

ValiRx Raises GBP200,000 To Progress Product Development

ValiRx Raises GBP200,000 To Progress Product Development

Read more
16 Dec 2019 10:17

ValiRx Reveals "Clear Impact" Of VAL201 On Prostate Cancer Patients

ValiRx Reveals "Clear Impact" Of VAL201 On Prostate Cancer Patients

Read more
28 Nov 2019 16:13

ValiRx granted US patent for 'VAL201' compound

(Sharecast News) - Clinical stage biotechnology company ValiRx announced on Thursday that the US Patent and Trademark Office has granted patent number 10,400,008, titled 'Modulators Of The SRC-Kinase Activity For Preventing Or Treating Metastatic Cancer', to its lead therapeutic compound 'VAL201'.

Read more
28 Nov 2019 15:57

ValiRx Granted "Key" US Patent Protection For VAL201 Cancer Treatment

ValiRx Granted "Key" US Patent Protection For VAL201 Cancer Treatment

Read more
14 Oct 2019 13:44

ValiRx Raises GBP350,000 Through Placing To Progress Clinical Trials

ValiRx Raises GBP350,000 Through Placing To Progress Clinical Trials

Read more
26 Sep 2019 11:43

ValiRx Reports Narrowed Loss In First Half As Expenses Reduce

ValiRx Reports Narrowed Loss In First Half As Expenses Reduce

Read more
24 Sep 2019 12:40

ValiRx Receives GBP423,000 Research & Development Credit From UK HMRC

ValiRx Receives GBP423,000 Research & Development Credit From UK HMRC

Read more
10 Sep 2019 13:45

ValiRx Prostate Cancer Drug VAL201 Still Meeting Endpoints

(Alliance News) - ValiRx PLC on Tuesday said its VAL201 lead compound is still meeting all of its published endpoints and is behaving as expected in prostate cancer.VAL201 has been as a and

Read more
1 Aug 2019 12:01

ValiRx Granted European Patent Allowance For VAL301 Compound

(Alliance News) - Clinical stage biotechnology firm ValiRx PLC said Thursday it has been granted a patent notice of allowance for its pre-clinical therapeutic compound, VAL301, from the European a

Read more
23 Jul 2019 16:25

Monecor Takes Nearly 6% Holding In Biotechnology Firm ValiRx

(Alliance News) - ValiRx PLC on Tuesday said Monecor London Ltd now holds 5.7% interest in the biotechnology company.Prior to this transaction on Monday, Monecor's holding totalled were

Read more
26 Jun 2019 14:30

US Grands Patent Claim For valiRx's VAL201 In Metastatic Cancer

(Alliance News) - ValiRx PLC on Wednesday said the US has allowed a patent claim for the use of VAL201 in metastatic cancer.Shares in ValiRx were down 7.1% at 0.21 pence in afternoon trade

Read more
26 Jun 2019 10:53

ValiRx gets US patent protection for use of VAL201 peptide

(Sharecast News) - Clinical stage biotechnology company ValiRx announced on Wednesday that the US Patent and Trademark Office (USPTO) has allowed patent claims directed towards a method of preventing the worsening of symptoms of metastatic cancer, reducing the progression of metastatic cancer, or treating metastatic cancer - including prostate cancer - by administration of the 'VAL201' peptide.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.